Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Bone Marrow and PBSC Transplantation
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Bone Marrow and PBSC Transplantation
    TopAbstracts in Bone Marrow and PBSC Transplantation 09/04/2008 - (DGNews)
    Intrabone Injection of Unrelated Cord-Blood Cells Prevents Graft Failure, Aids Haemopoietic Recovery - (DGNews)
    TopAbstracts in Bone Marrow and PBSC Transplantation 08/07/2008 - (DGNews)
    TopAbstracts in Bone Marrow and PBSC Transplantation 07/24/2008 - (DGNews)
    TopAbstracts in Bone Marrow and PBSC Transplantation 07/10/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Bone Marrow and PBSC Transplantation
    Noninfectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation

    Webcasts/CME archive

     Recent cases - Bone Marrow and PBSC Transplantation
      Minimal Change Nephrotic Syndrome after Stem Cell Transplantation: A Case Report and Literature Review
      Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Case Report
      B-Cell Recovery after Stem Cell Transplantation of Artemis-Deficient SCID Requires Elimination of Autologous Bone Marrow Precursor-B-Cells
      Intra-Arterial Autologous Bone Marrow Mononuclear Cell Transplantation for Acute Ischemic Stroke
      Ineffective Off-Label Use of Recombinant Activated Factor VII in a Case of Bone-Marrow Transplantation-Related Gastrointestinal Bleeding

      Cases archive
        




      my personal edition > bone marrow and pbsc transplantation > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Positive Long-Term Outcome Reported for 5-Year Survivors of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Presented at ASBMT

      By Alan McClelland

      HONOLULU, HI -- February 21, 2006 -- According to the results of the largest study of patient outcomes in allogeneic hemaotopoietic stem cell transplantation (allo-HSCT) for chronic myelogenous leukemia (CML) ever performed, 87% of patients who survived for 5 years were still alive 15 years after transplantation.

      In an analysis of 8738 patients who received donor cell transplantation between 1978 and 1998, 2954 patients were alive and cancer free 5 years post-transplantation.

      The Chronic Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research analyzed the long term outcome in these patients. John M. Goldman, MD, Clinical Professor, Division of Investigative Science, Medicine, Imperial College London, London, United Kingdom, presented the results at the 2006 Blood and Marrow Transplant Tandem Meetings (ASBMT) on February 16th.

      The first allo-HSCT procedures for CML were performed in 1978. By the 1980s a large number of these transplants were being done, with the perception by 1990 that patients who had done well in the initial years after transplantation were cured of their disease.

      However, in this large study, during the 10 year period of patient follow up, approximately 10% of patients experienced a relapse of their leukemia. The latest relapse occurred 16 years after transplantation, according to Dr. Goldman.

      By comparing the relative rate of mortality in the 5 year survivors to controls who were matched for age, sex and race, and nationality, the investigators showed that after 15 years, the death rate for these patients approaches that of the general population, suggesting that there is a declining risk of excess mortality with time.

      The investigators identified several factors that predicted an increased risk of death. These include the age of the patient at time of transplant, use of total body irradiation in the conditioning regimen, chronic graft versus host disease (GVHD), transplantation from a female donor to a male recipient.

      Of the 227 deaths in the study population, 17% were due to CML disease and 15% to chronic GVHD, with the remainder due to infection, organ failure and other causes.

      "We conclude that the majority of remissions after allo-HSCT looked at beyond 5 years are durable, but that there is a low but constant rate of relapse that persists for greater than 15 years," Dr. Goldman said.


      [Presentation title: Long-Term Outcome After Allogeneic Hematopoietic Cell Transplantation for CML: Abstract 40]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send